Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?

References

• Blaha P, Dubsky P, Fitzal F et al. Breast cancer chemoprevention – a vision not yet realized. Eur. J. Cancer Care18(5), 438–446 (2009).
   PubMed Web of Science ®Google Scholar
• Nelson HD, Fu R, Humphrey L, Smith MEB, Griffin JC, Nygren P. Comparative effectiveness of medications to reduce risk of primary breast cancer in women. Agency for Healthcare Research and Quality. 09-EHC028-EF (2009).
   Google Scholar
• Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J. Natl Cancer Inst.95(7), 526–532 (2003).
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA295(23), 2727–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan CP, Haas JS, Perez-Stable EJ et al. Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol. Biomarkers Prev.15(1), 162–166 (2006).
   PubMed Web of Science ®Google Scholar
• Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch. Intern. Med.166(20), 2260–2265 (2006).
   PubMedGoogle Scholar
• Visvanathan K, Chlebowski RT, Hurley P et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol.27(19), 3235–3258 (2009).
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med.340(2), 77–84 (1999).
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol.22(6), 1055–1062 (2004).
   PubMed Web of Science ®Google Scholar
• Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst. Rev.4, CD002748 (2004).
   Google Scholar
• Bevers TB, Anderson BO, Bonaccio E et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J. Natl Compr. Canc. Network7(10), 1060–1096 (2009).
   PubMed Web of Science ®Google Scholar
• McLaughlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005. Cancer115(23), 5404–5412 (2009).
   PubMed Web of Science ®Google Scholar
• Ingle JN, Suman VJ, Johnson PA et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin. Cancer Res.5(7), 1642–1649 (1999).
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst.95(23), 1758–1764 (2003).
   PubMed Web of Science ®Google Scholar
• Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst.97(1), 30–39 (2005).
   PubMed Web of Science ®Google Scholar
• Clarke R, Liu MC, Bouker KB et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene22(47), 7316–7339 (2003).
   PubMed Web of Science ®Google Scholar
• Jaremko M, Kasai Y, Barginear MF et al. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. Anal. Chem.82(24), 10186–10193 (2010).
   PubMed Web of Science ®Google Scholar
• Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res.48(8), 2304–2308 (1988).
   PubMed Web of Science ®Google Scholar
• Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther.80(1), 61–74 (2006).
   PubMed Web of Science ®Google Scholar
• Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther.310(3), 1062–1075 (2004).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J.5(1), 6–13 (2005).
   PubMed Web of Science ®Google Scholar
• Gross AS, Kroemer HK, Eichelbaum M. Genetic polymorphism of drug metabolism in humans. Adv. Exp. Med. Biol.283, 627–640 (1991).
   PubMedGoogle Scholar
• Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics17(2), 93–101 (2007).
   PubMed Web of Science ®Google Scholar
• Sideras K, Ingle JN, Ames MM et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J. Clin. Oncol.28(16), 2768–2776 (2010).
   PubMed Web of Science ®Google Scholar
• Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn. Schmiedebergs. Arch. Pharmacol.369(1), 23–37 (2004).
   PubMed Web of Science ®Google Scholar
• Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res.69(5), 1722–1727 (2009).
   PubMed Web of Science ®Google Scholar
• Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol.25(25), 3837–3845 (2007).
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Imamura CK et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol.28(8), 1287–1293 (2010).
   PubMed Web of Science ®Google Scholar
• Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol.23(36), 9312–9318 (2005).
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat.101(1), 113–121 (2007).
   PubMed Web of Science ®Google Scholar
• Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol.25(33), 5187–5193 (2007).
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA302(13), 1429–1436 (2009).
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci.99(5), 995–999 (2008).
   PubMed Web of Science ®Google Scholar
• Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat.91(3), 249–258 (2005).
   PubMed Web of Science ®Google Scholar
• Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res.9(1), R7 (2007).
   PubMed Web of Science ®Google Scholar
• Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res.7(3), 284–290 (2005).
   PubMed Web of Science ®Google Scholar
• Xu Y, Sun Y, Yao L et al. Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol.19(8), 1423–1429 (2008).
   PubMed Web of Science ®Google Scholar
• Ramon y Cajal T, Altes A, Pare L et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res. Treat.119(1), 33–38 (2009).
   PubMed Web of Science ®Google Scholar
• Bijl MJ, van Schaik RH, Lammers LA et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat.118(1), 125–130 (2009).
   PubMed Web of Science ®Google Scholar
• Newman WG, Hadfield KD, Latif A et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin. Cancer Res.14(18), 5913–5918 (2008).
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer9(8), 576–586 (2009).
   PubMed Web of Science ®Google Scholar
• Lash TL, Rosenberg CL. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J. Clin. Oncol.28(8), 1273–1275 (2010).
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Hosono N et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet. Genomics20(9), 565–568 (2010).
   PubMed Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol. Biomarkers Prev.18(9), 2562–2564 (2009).
   PubMed Web of Science ®Google Scholar
• Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br. Med. J.340, c693 (2010).
   PubMed Web of Science ®Google Scholar
• Azoulay L, Dell’aniello S, Huiart L, du Fort GG, Suissa S. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res. Treat. DOI: 10.1007/s10549-010-1162-y (2010) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Siegelmann-Danieli N, Kurnik D, Lomnicky Y et al. Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res. Treat.125(2), 505–510 (2010).
   PubMed Web of Science ®Google Scholar
• Desmarais JE, Looper KJ. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas67(4), 296–308 (2010).
   PubMed Web of Science ®Google Scholar
• Dezentjé VO, van Blijderveen NJ, Gelderblom H et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J. Clin. Oncol.28(14), 2423–2429 (2010).
   PubMed Web of Science ®Google Scholar
• Ferraldeschi R, Howell SJ, Thompson AM et al. Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J. Clin. Oncol.28(29), e584–e585 (2010).
   PubMed Web of Science ®Google Scholar
• Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer115(5), 952–961 (2009).
   PubMed Web of Science ®Google Scholar